Clinical Trials Logo

Atopic Dermatitis (AD) clinical trials

View clinical trials related to Atopic Dermatitis (AD).

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05959083 Active, not recruiting - Clinical trials for Atopic Dermatitis (AD)

Real World Study of Oral Upadacitinib Tablets to Assess Adverse Events and Change in Disease Activity in Adolescent and Adult Chinese Participants With Atopic Dermatitis

Start date: August 18, 2023
Phase:
Study type: Observational

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. This study will assess how safe and effective upadacitinib is in treating AD in adolescent and adult Chinese participants. Upadacitinib is an approved drug for treating AD. Approximately 200 adolescent and adult participants who are prescribed upadacitinib by their physician in accordance with local label will be enrolled in China. Participants will receive upadacitinib as prescribed by their physician according to their routine clinical practice and local label. Participants will be followed up for approximately 24 months per participant and 30 days after last treatment dose for safety data collection. There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice

NCT ID: NCT05456529 Active, not recruiting - Clinical trials for Atopic Dermatitis (AD)

Study of Ruxolitinib Cream in Adolescents With Atopic Dermatitis

Start date: September 1, 2022
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the long-term safety and tolerability of ruxolitinib cream in adolescents with Atopic Dermatitis (AD).